1,101 Shares in Zoetis Inc. (NYSE:ZTS) Acquired by GUNN & Co INVESTMENT MANAGEMENT INC.

GUNN & Co INVESTMENT MANAGEMENT INC. bought a new position in Zoetis Inc. (NYSE:ZTS) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 1,101 shares of the company’s stock, valued at approximately $217,000.

Several other institutional investors also recently bought and sold shares of the business. Blue Bell Private Wealth Management LLC increased its stake in Zoetis by 222.5% in the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after purchasing an additional 89 shares during the last quarter. Independence Bank of Kentucky increased its stake in shares of Zoetis by 371.4% during the 4th quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock valued at $33,000 after acquiring an additional 130 shares during the last quarter. Ramirez Asset Management Inc. purchased a new position in shares of Zoetis during the 3rd quarter worth about $35,000. First Financial Corp IN boosted its position in shares of Zoetis by 57.2% in the fourth quarter. First Financial Corp IN now owns 217 shares of the company’s stock worth $43,000 after acquiring an additional 79 shares during the last quarter. Finally, Bogart Wealth LLC grew its holdings in Zoetis by 188.9% in the third quarter. Bogart Wealth LLC now owns 260 shares of the company’s stock valued at $45,000 after purchasing an additional 170 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Roxanne Lagano sold 923 shares of the firm’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $173.33, for a total transaction of $159,983.59. Following the completion of the sale, the executive vice president now directly owns 15,723 shares in the company, valued at $2,725,267.59. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 2,209 shares of company stock valued at $371,293 in the last quarter. Company insiders own 0.16% of the company’s stock.

Zoetis Trading Down 0.1 %

Shares of ZTS opened at $167.07 on Monday. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The stock’s 50-day moving average is $168.88 and its two-hundred day moving average is $178.93. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00. The stock has a market cap of $76.41 billion, a PE ratio of 32.19, a P/E/G ratio of 2.61 and a beta of 0.86.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.34 by $0.04. Zoetis had a return on equity of 50.74% and a net margin of 27.38%. The firm had revenue of $2.19 billion for the quarter, compared to analyst estimates of $2.14 billion. During the same period in the previous year, the company posted $1.31 EPS. Zoetis’s revenue for the quarter was up 9.5% on a year-over-year basis. Equities analysts forecast that Zoetis Inc. will post 5.77 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be issued a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 1.03%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s payout ratio is 33.33%.

Analysts Set New Price Targets

A number of equities analysts have weighed in on ZTS shares. Piper Sandler reaffirmed an “overweight” rating and set a $195.00 price target (down previously from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Stifel Nicolaus reduced their target price on Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, April 30th. The Goldman Sachs Group boosted their price target on Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Finally, Barclays decreased their target price on Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 23rd. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $216.13.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.